Diabetes Mellitus and Lipoprotein(a): A Determinant Interaction in Micro- and Macrovascular Damage
Authors:
- Alberto Polo-BarrancoAPAlberto Polo-Barranco
- Carlos Rebolledo-MaldonadoCRCarlos Rebolledo-Maldonado
- Valeria Esquiaqui-RangelVEValeria Esquiaqui-Rangel
- Andrea Nuñez-MejiaANAndrea Nuñez-Mejia
- Jeison Rambal-TorresJRJeison Rambal-Torres
- Valentina Barraza-AhumadaVBValentina Barraza-Ahumada
- Shivleivy Vargas-CantilloSVShivleivy Vargas-Cantillo
- Wylman Benavides-De la CruzWCWylman Benavides-De la Cruz
- Valentina Liñán-MartínezVLValentina Liñán-Martínez
- Valentina Rada-ObesoVRValentina Rada-Obeso
- Muna Aylisha Isaac-EscorciaMIMuna Aylisha Isaac-Escorcia
- Neil Martínez-FontalvoNMNeil Martínez-Fontalvo
Preprint
- 17 November 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Diabetes mellitus (DM) is associated with a residual cardiovascular risk that persists even when lipid targets are achieved. Within this context, lipoprotein(a) [Lp(a)], an LDL-like particle of genetic origin with pro-atherogenic and antifibrinolytic properties, emerges as a key determinant in the progression of both microvascular and macrovascular complications. Its structural homology with plasminogen promotes thrombosis, while oxidative and glycation modifications amplify endothelial inflammation. Elevated concentrations of Lp(a) (>30 mg/dL; 75 nmol/L), and particularly >50 mg/dL (125 nmol/L), are independently associated with coronary artery disease, ischemic stroke, diabetic nephropathy, retinopathy, and neuropathy. Conventional lipid-lowering therapies exert neutral or modest effects on Lp(a), in contrast with RNA-based targeted agents (antisense oligonucleotides and siRNA[Small Interfering RNA]), which achieve reductions of 70–95% and show consistent results in phase 2 clinical trials. This review integrates molecular mechanisms and clinical evidence, emphasizing the need to incorporate Lp(a) quantification (at least once in a lifetime, and selectively in DM) to refine risk stratification and guide intensive interventions. In diabetic populations, the adaptation of Lp(a)-targeted therapies could redefine the management of residual risk and improve both cardiovascular and microvascular outcomes.Keywords
All Related Versions
This publication has 206 references indexed in Scilit:
- Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)JAMA, 2023
- Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) FormationJAMA, 2023
- Lipoprotein(a) and its Significance in Cardiovascular DiseaseJAMA Cardiology, 2022
- Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) LevelsJAMA, 2022
- Association ofLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering TherapiesJAMA Cardiology, 2018
- ‘Lipoproteins, glycoxidation and diabetic angiopathy’Diabetes/Metabolism Research and Reviews, 2004
- The AGE‐receptor in the pathogenesis of diabetic complicationsDiabetes/Metabolism Research and Reviews, 2001
- The role of oxidative stress and NF‐κB activation in late diabetic complicationsBioFactors, 1999
- Maturity‐onset diabetes of the young (MODY)Diabetes/Metabolism Research and Reviews, 1989
- Retinal Vascular PatternsArchives of Ophthalmology (1950), 1961